BRAF and neoplasm: Moving towards using ctDNA as a potential tool to guide clinical decisions, the Circulating Tumour DNA Guided Switch (CAcTUS; NCT03808441) phase II feasibility trial in patients with BRAF mutant melanoma is examining whether response to ICI can be improved through pre-treatment with targeted therapy and switching treatment in response rather than resistance [49••].